Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cannizzaro, R., Robieux, I., Valentini, M., Sorio, R., Amo roso, B., Tumolo, S. & Campagnutta, E. (1996). Liver function assessment by MEGX: application to oncology. Ann NY Acad Sci 784: 486–490.
Dobbs, N. A. & Twelves, C. J. (1998). Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? Br J Cancer 77: 1145–1148.
Fevery, J. & Blanckaert, N. (1991). Hyperbilirubinaemia. In Oxford Textbook of Clinical Hepatology, McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J (eds), pp. 985–991. Oxford University Press: Oxford
Hryniuk, W. M., Bonadonna, G. & Valagussa, P. (1987). The effect of dose intensity in adjuvant chemotherapy. In Adjuvant Therapy of Cancer, Salmon JE (ed), pp. 13–23. Grusse & Strastton: Orlando
Saksena, S. & Tandon, R. K. (1997). Ursodeoxycholic acid in the treatment of liver disease. Postgrad Med J 73: 75–80.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cannizzaro, R., Crivellari, D., Robieux, I. et al. Anthracycline dose and liver dysfunction. Br J Cancer 79, 1943 (1999). https://doi.org/10.1038/sj.bjc.6690310
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690310